European stocks closed weak on Thursday, as hotter-than-expected U.S. consumer price inflation data has further offset optimism the ...

Patients shouldn’t rely on AI powered search engines and chatbots to always give them  accurate and safe information on drugs, conclude researchers in the journal BMJ Quality & Safety, after finding a ...

The new approval bolsters AZ's position in what is becoming a battle with GSK and MSD in first-line endometrial cancer, with Imfinzi and Imfinzi/Lynparza pitted against the GSK's Jemperli ...

Belgium and France meet again on Monday with the second of their two UEFA Nations League games in Brussels having also met at ...

The Company has developed total 5 (five) specialised precision parts for the said project and have submitted the samples and trail batches in past 12 (Twelve) months, now the company has received the ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...

At the same time, Moody's Ratings delivered a cut to its rating outlook for Belgium. “The decision to change the outlook to negative from stable reflects the risk that the next government will be ...

GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British ...

GSK’s shares rose by as much as 6.5% on Thursday before settling back slightly lower after it agreed a $2.2 billion settlement over lawsuits in the US, which alleged the drugmaker’s now ...

Settlement resolves 80,000 or 93% of pending US cases GSK top gainer on FTSE-100, best one-day gain since Dec 2022 To record 1.8 billion pounds charge in Q3 results Oct 10 (Reuters) - GSK (GSK.L ...